Showing results (1171-1180 of 1,351) with videos related to
Sort By:
Pageof 136
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2023
Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitorsK D Lewis, K Peris, A Sekulic, et al.Journal of Translational Medicine|May 4, 2012
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011"Paolo A Ascierto, Antonio M Grimaldi, Brendan Curti, et al.European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsDirk Schadendorf, Georgina V Long, Daniil Stroiakovski, et al.Translational Psychiatry|February 16, 2021
Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant responseVictoria S Marshe, Malgorzata Maciukiewicz, Anne-Christin Hauschild, et al.Journal for Immunotherapy of Cancer|August 20, 2021
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysisDanny Rischin, Nikhil I Khushalani, Chrysalyne D Schmults, et al.The British Journal of Dermatology|February 13, 2018
A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapyC A Morton, R Dominicus, P Radny, et al.The Journal of Prevention of Alzheimer'S Disease|May 22, 2026
Hypertension acts together with Aβ pathology in late-life to promote memory lossLucas U Da Ros, João Pedro Ferrari-Souza, Marco Antônio de Bastiani, et al.Cancers|April 12, 2022
Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in GermanyPeter Mohr, Emilie Scherrer, Chalid Assaf, et al.The Lancet. Oncology|February 11, 2014
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyGrant A McArthur, Paul B Chapman, Caroline Robert, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 25, 2024
S2k guideline basal cell carcinoma of the skin (update 2023)Berenice M Lang, Panagiotis Balermpas, Andrea Bauer, et al.Pageof 136